AGP Picks
View all

Vyepti market report points to steady global growth through 2035

6 hours ago
Vyepti market report points to steady global growth through 2035
By AI, Created 14:45 UTC, Nov 19, 2026, AGP -

The Business Research Company says the Vyepti market is expanding as chronic migraine cases rise and biologic therapies gain wider use. The report highlights North America’s lead, growing healthcare spending, and new trends in CGRP-targeted and long-acting migraine treatments.

Why it matters: - The Vyepti market is being pulled by rising demand for preventive migraine care and broader use of biologic treatments. - The report frames Vyepti as part of a larger shift toward targeted migraine therapies with longer-lasting effects. - Growth in this market has implications for neurology clinics, infusion-based care, and biologic drug developers.

What happened: - The Business Research Company published its Vyepti Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 19, 2026. - The report says the Vyepti market has gained attention as demand for advanced migraine treatments grows globally. - The report identifies North America as the largest regional market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

The details: - Vyepti is the brand name for eptinezumab-jjmr. - Vyepti is designed to prevent chronic migraines in adults. - Vyepti is a monoclonal antibody that targets calcitonin gene-related peptide, or CGRP. - Blocking CGRP helps reduce the frequency of migraine attacks. - Historical market growth has been supported by higher chronic migraine prevalence, more neurological disorder diagnoses, and wider acceptance of biologic migraine therapies. - Specialty neurology clinics and better access to advanced treatment options have also supported demand. - Future growth is expected to be driven by next-generation monoclonal antibodies, personalized neurology treatment, larger biologic drug pipelines, and therapies with longer-lasting effects. - Emerging trends include wider use of CGRP-targeted migraine medications, more long-acting preventive solutions, growth in biologic neurological drugs, hospital-based infusion therapies, and personalized migraine management. - The report’s 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The report links market expansion to both disease burden and health-system investment, suggesting Vyepti’s outlook depends on access as much as on clinical demand. - North America’s lead appears tied to advanced healthcare infrastructure, high patient awareness, and broad adoption of innovative migraine therapies. - The emphasis on CGRP-targeted and long-acting treatments shows where competitive pressure and product development are likely to concentrate.

What's next: - The report expects steady market expansion through 2035. - Continued investment in healthcare and biologic pipelines may broaden access to advanced migraine care. - Regional growth outside North America will depend on infrastructure, affordability, and adoption of newer treatment models.

The bottom line: - Vyepti sits in a growing migraine-treatment market that is being shaped by chronic disease burden, biologic innovation, and expanding access to care.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Global Healthcare Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Global Healthcare Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.